(0.34%) 5 117.15 points
(0.32%) 38 362 points
(0.38%) 15 988 points
(-0.88%) $83.11
(5.98%) $2.04
(0.41%) $2 356.80
(0.42%) $27.65
(3.90%) $958.10
(-0.22%) $0.933
(-0.38%) $10.98
(-0.54%) $0.796
(1.66%) $93.40
@ $2.18
発行日: 15 2月 2024 @ 04:06
リターン: -62.32%
前回のシグナル: 2月 14 - 05:42
前回のシグナル:
リターン: 3.82 %
Live Chart Being Loaded With Signals
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases...
Stats | |
---|---|
本日の出来高 | 591 034 |
平均出来高 | 2.90M |
時価総額 | 87.20M |
EPS | $0 ( 2024-03-14 ) |
次の収益日 | ( $-0.300 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.680 |
ATR14 | $0.00200 (0.24%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-01 | Hawryluk Matthew | Buy | 35 000 | Common Stock |
2024-02-01 | Hawryluk Matthew | Buy | 180 000 | Stock Option (Right to Buy) |
2024-02-01 | Jones Erin | Buy | 40 000 | Common Stock |
2024-02-01 | Jones Erin | Buy | 235 000 | Stock Option (Right to Buy) |
2024-02-01 | Economides Vassiliki | Buy | 35 000 | Common Stock |
INSIDER POWER |
---|
100.00 |
Last 97 transactions |
Buy: 5 929 842 | Sell: 139 571 |
ボリューム 相関
Gritstone Oncology Inc 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Gritstone Oncology Inc 相関 - 通貨/商品
Gritstone Oncology Inc 財務諸表
Annual | 2023 |
収益: | $1.33M |
総利益: | $-6.26M (-470.32 %) |
EPS: | $-1.200 |
FY | 2023 |
収益: | $1.33M |
総利益: | $-6.26M (-470.32 %) |
EPS: | $-1.200 |
FY | 2022 |
収益: | $9.27M |
総利益: | $-6.42M (-69.28 %) |
EPS: | $-1.240 |
FY | 2021 |
収益: | $48.21M |
総利益: | $48.21M (100.00 %) |
EPS: | $-0.965 |
Financial Reports:
No articles found.
Gritstone Oncology Inc
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors comprising metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and shared neoantigen-positive tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. It has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。